Preoperative (direct) oral anticoagulants and secondary hemorrhage after TURP

被引：0

作者：

van der Velde-Kemmeren A.A.T.M. ^{[1
]}

Zwaan P.J. ^{[1
]}

Bossema E.R. ^{[2
]}

机构：

[1] afdeling Urologie, Gelre ziekenhuizen, Apeldoorn/Zutphen

[2] Master Advanced Nursing Practice, Hogeschool van Arnhem en Nijmegen, Nijmegen

来源：

Tijdschrift voor Urologie | 2020年 / 10卷 / 4期

关键词：

(D)OAC; secondary hemorrhage; TURP;

D O I：

10.1007/s13629-019-00272-9

中图分类号：

学科分类号：

摘要：

Transurethral resection of the prostate (TURP) is used to treat benign prostatic enlargement. This study investigated whether the preoperative use of (direct) oral anticoagulants ((D)OAC) is related to secondary hemorrhage after TURP. From men who had undergone bipolar TURP in 2016 or 2017, data were collected regarding the preoperative use of OAC, secondary hemorrhage, and re-hospitalization until four weeks after TURP. In 15% of the 376 patients secondary hematuria occurred, that is, in 24% with preoperative OAC use (particularly DOAC) and in 9% without preoperative OAC use (p < 0.001). For 5% re-hospitalization was necessary, that is, for 7% with preoperative OAC use (particularly DOAC) and for 3% without preoperative OAC use (p = 0.10). Patients undergoing TURP and using OAC preoperatively, particularly DOAC, possibly have an increased risk of developing secondary hemorrhage. However, further research with more patients is needed to confirm the results. © 2019, The Author(s).

引用

页码：72 / 77

页数：5

共 17 条

[1]

Oesterling J.E., The origin and development of benign prostatic hyperplasia. An age-dependent process, J Androl, 12, 6, pp. 348-355, (1991)

[2]

Richtlijn Diagnostiek En Behandeling Van LUTS/BPH, (2006)

[3]

Rassweiler J., Teber D., Kuntz R., Hofmann R., Complications of transurethral resection of the prostate (TURP)—Incidence, management and prevention, Eur Urol, 50, 5, pp. 969-979, (2006)

[4]

Richtlijn mannelijke niet-neurogene LUTS, (2017)

[5]

Lynch M., Sriprasad S., Subramonian K., Thompson P., Postoperative haemorrhage following transurethral resection of the prostate (TURP) and photoselective vaporisation of the prostate (PVP), Ann R Coll Surg Engl, 92, 7, pp. 555-558, (2010)

[6]

Lebdai S., Robert G., Devonnec M., Et al., Management of patients under anticoagulants for transurethral resection of the prostate: a multicentric study bij the CTMH-AFU, Prog Urol, 19, 8, pp. 553-557, (2009)

[7]

Yee C.H., Wong J.H., Chiu P.K., Et al., Secondary hemorrhage after bipolar transurethral resection and vaporization of prostate, Urol Ann, 8, 4, pp. 458-463, (2016)

[8]

Descazeaud A., Robert G., Lebdai S., Et al., Impact of oral anticoagulation on morbididty of transurethral resection of the prostate, World J Urol, 29, 2, pp. 211-216, (2011)

[9]

Palmisano F., Boeri L., Fontana M., Et al., Incidence and predictors of readmission within 30 days of transurethral resection of the prostate: a single center European experience, Sci Rep, 8, 1, (2018)

[10]

Douketis J.D., Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for clinicians, Thromb Res, 108, 1, pp. 3-13, (2002)

← 1 2 →